MRGPRX2 in drug allergy: What we know and what we do not know

Affiliations

¹ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: pavel.kolkhir@charite.de.
² Department of Basic and Translational Sciences, University of Pennsylvania, School of Dental Medicine, Philadelphia, Pa.
³ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
⁴ Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital, Antwerp, Belgium.
⁵ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: marcus.maurer@charite.de.

Editorial

Pavel Kolkhir et al. J Allergy Clin Immunol. 2023 Feb.

. 2023 Feb;151(2):410-412.

doi: 10.1016/j.jaci.2022.09.004. Epub 2022 Sep 9.

¹ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: pavel.kolkhir@charite.de.
² Department of Basic and Translational Sciences, University of Pennsylvania, School of Dental Medicine, Philadelphia, Pa.
³ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
⁴ Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp University Hospital, Antwerp, Belgium.
⁵ Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. Electronic address: marcus.maurer@charite.de.

No abstract available

Keywords: MRGPRX2; NMBA; anaphylaxis; antibiotics; drug allergy; drug hypersensitivity; mast cells; vancomycin.

Figures

1. Porebski G, Kwiecien K, Pawica M & Kwitniewski M Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Front. Immunol 9, 3027., doi:10.3389/fimmu.2018.03027 (2018). - DOI - PMC - PubMed
1. McNeil BD MRGPRX2 and Adverse Drug Reactions. Frontiers in Immunology 12, doi:10.3389/fimmu.2021.676354 (2021). - DOI - PMC - PubMed
1. McNeil BD et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519, 237–241, doi:10.1038/nature14022 (2015). - DOI - PMC - PubMed
1. Elst J et al. Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones. Front Immunol 12, 668962, doi:10.3389/fimmu.2021.668962 (2021). - DOI - PMC - PubMed
1. Van Gasse AL et al. Rocuronium Hypersensitivity: Does Off-Target Occupation of the MRGPRX2 Receptor Play a Role? J Allergy Clin Immunol Pract 7, 998–1003, doi:10.1016/j.jaip.2018.09.034 (2019). - DOI - PubMed